CSF β-amyloid is not a prognostic marker in multiple sclerosis patients

Area of Science:

• Neuroimmunology
• Biomarker Discovery

Background:

• Multiple sclerosis (MS) is a leading cause of chronic inflammatory demyelination with variable prognosis.
• Identifying reliable prognostic biomarkers is crucial for effective MS management.

Purpose of the Study:

• To investigate the prognostic value of cerebrospinal fluid (CSF) beta-amyloid-42 (Aβ42) and beta-amyloid-40 (Aβ40) levels in MS patients.
• To assess the potential of CSF amyloid levels as biomarkers for MS status and disease progression.

Main Methods:

• Retrospective analysis of clinical, MRI, and CSF data from 89 recently diagnosed MS patients (55 RRMS, 34 PPMS) and 27 controls.
• Evaluation of CSF Aβ42 and Aβ40 levels and their ratio.
• Multivariate analysis considering age and Expanded Disability Status Scale (EDSS).
• 3-year follow-up of 55 RRMS patients to assess disability progression.

Main Results:

• CSF amyloid-beta (Aβ) levels and Aβ42/Aβ40 ratio did not differ between MS patients and controls.
• Higher CSF Aβ42 and Aβ40 levels were observed in primary progressive MS (PPMS) compared to relapsing-remitting MS (RRMS) and in patients with higher EDSS.
• Only patient age, not EDSS or MS subtype, was associated with CSF amyloid levels in multivariate analysis.
• No correlation was found between baseline CSF amyloid levels and 3-year disability progression in RRMS patients.

Conclusions:

• CSF amyloid levels are not associated with MS status or disease severity.
• CSF amyloid levels do not appear to be a prognostic biomarker in recently diagnosed RRMS.
• Further research may be needed to identify reliable prognostic markers for MS.